


# PROSTATE STAGING DIAGRAM

|         | UNIT                 |
|---------|----------------------|
|         | AGENCY CHART No.     |
| SURNAME | GIVEN NAME           |
| D 0.0   | HEALTH CARE PLAN No. |



| L.  |           |             | المنتخذا    |         | F                                      | ₹.       |          |          |              |                     |                   |                                    |                       |                |
|---|-----------|-------------|-------------|---------|--|----------|----------|----------|--------------|---------------------|-------------------|------------------------------------|-----------------------|----------------|
| Gleason:                                    | (1        | -5) + _     | N Telephone | _(1-5)  | Total:                                 |          | (2-1     | 0)       | PSA pretreat | ment and            | within t          | wo month                           | ng/ml<br>s of staging | reference date |
| # of Biopsies                               | s +ve:    |             |             |         | _Total #                               | of Bid   | opsies   | done:    | -            |                     |                   |                                    |                       |                |
| HISTOLOG                                    | Y:        | 20-3007     |             |         |  |          |          |          |              |                     | 3000              |                                    |                       |                |
| NEW Referred as pa RECURF Definitive treatr | RENT or   | META:       | STATIC      | DISE    | ASE                                    |          | )        | Ref      | erred afte   | er radica<br>RRED I | l prosta<br>FOR F | CTOMY<br>atectomy<br>FOLLOWed else |                       | e referral     |
| Stage reflects of Prefix Y:                 | Id        | entifies    | cases ir    | which s | t or at ref<br>staging po<br>therapy o | erformed | d during |          |              |                     |                   |                                    | t diagnosis.          | 6              |
| TNM 2002<br>Clinical/                       | *         | T<br>N      | X           | 0       | 1a<br>1                                | 1b       | 1c       | 2a       | 2b           | 2c                  | 3a                | 3b                                 | 4                     |                |
| Radiological                                |           | M           | X           | 0       | 1a                                     | 1b       | 1c       | Meta     | astatic      | site(s):            |                   |                                    |                       |                |
| TNM 2002                                    | *         | Т           | X           | 0       | **                                     |          |          | 2a       | 2b           | 2c                  | 3a                | 3b                                 | 4                     |                |
| Pathological                                |           | N<br>M      | X           | 0       | 1<br>1a                                | 1b       | 1c       | Meta     | astatic      | site(s):            |                   |                                    |                       |                |
| ** There is no p                            | athologic | T1 class    | sification  | ı       |  |          |          |          |              |                     |                   |                                    |                       |                |
| Completed b                                 | oy:       | W. Carlotte |             | Unicole |  |          |          |          | uprate -     |                     |                   | Date:                              |                       |                |
| Diagnosis/S                                 | tage am   | ended       | to: _       |         |  |          |          |          |              |                     |                   |                                    |                       |                |
| Reason:                                     |           |             | _           |         |  |          |          |          |              |                     |                   |                                    |                       | 7139           |
| Ву:   |           |             |             |         |  |          |          |          |              |                     |                   |                                    |                       |                |
|   | NOTIFY    | PATIE       | NT INF      | ORMA    | HON M                                  | ANAGE    | MENT     | (PIM) II | F STAG       | E/DIAG              | NOSIS             | S IS AM                            | ENDED                 |                |

00053817 (FRC-46) Revised December 2002

#### **PROSTATE**

## TNM 2002 CLINICAL AND PATHOLOGICAL CLASSIFICATION

### CLINICAL

#### PATHOLOGICAL

|   |        | CLINICAL   |                   | PATHOLOGICAL   |  |  |  |  |  |
|---|--------|--|-------------------|--|--|--|--|--|--|
| T   | PRIM   | MARY TUMOUR  | Т                 | PRIMARY TUMOUR   |  |  |  |  |  |
| TX  | Prima  | ary tumour cannot be assessed                                    | χΤq               |  |  |  |  |  |  |
| TO  | No e   | vidence of primary tumour  | рТО               |  |  |  |  |  |  |
| T1  | Clinic | cally inapparent tumour not palpable or visible by imaging       | **                | tumoul   |  |  |  |  |  |
|   | 1a     | Tumour incidental histological finding in 5% or less of          |                   |  |  |  |  |  |  |
|   |        | tissue resected  | * Th              | here is no pathologic T1 classification  |  |  |  |  |  |
|   | 1b     | Tumour incidental histological finding in more than              |                   | p and give it elegations   |  |  |  |  |  |
|   |        | 5% of tissue resected  |                   |  |  |  |  |  |  |
|   | 1c     | Tumour identified by needle biopsy (eg. because of               |                   |  |  |  |  |  |  |
| 2000  |        | elevated PSA)  |                   |  |  |  |  |  |  |
| T2  |        | ur confined within the prostate*                                 | pT2               | Organ confined   |  |  |  |  |  |
|   | 2a     | Tumour involves one-half of 1 lobe or less                       | N. Berry S. Brand | 2a Unilateral, involving one-half of 1 lobe or   |  |  |  |  |  |
|   | 2b     | Tumour involves more than one-half of 1 lobe but not             |                   | less   |  |  |  |  |  |
|   | menteo | both lobes   |                   | 2b Unilateral, involving more than one-half of   |  |  |  |  |  |
|   | 2c     | Tumour involves both lobes                                       |                   | 1 lobe, but not both lobes   |  |  |  |  |  |
| T3  | Tumo   | ur extends through the prostate capsule**                        |                   | 2c Bilateral disease   |  |  |  |  |  |
|   | 3a     | Extracapsular extension (unilateral or bilateral)                | pT3               |  |  |  |  |  |  |
|   | 3b     | Tumour invades seminal vesicle(s)                                |                   | 3a Extraprostatic extension **   |  |  |  |  |  |
| T4  | lumo   | ur is fixed or invades adjacent structures other than            |                   | 3b Seminal vesicle invasion  |  |  |  |  |  |
|   | semin  | nal vesicles; bladder neck, external sphincter, rectum,          | pT4               |  |  |  |  |  |  |
| *   | levato | r muscles and/or pelvic wall                                     |                   |  |  |  |  |  |  |
|   | lumo   | ur found in one or both lobes by needle biopsy, but not          | **                | Positive surgical margin should be indicated by an   |  |  |  |  |  |
| **  | paipai | ble or reliably visible by imaging, is classified as T1c         |                   | R1 descriptor (residual microscopic disease)   |  |  |  |  |  |
|   | rivasi | on into the prostatic apex or into (but not beyond) the          |                   | 10 to  |  |  |  |  |  |
|   | prosta | atic capsule is classified not as T3 but as T2                   |                   |  |  |  |  |  |  |
| N   | REGI   | ONAL LYMPH NODES   | рΝ                | REGIONAL LYMPH NODES   |  |  |  |  |  |
|   |        | The regional lymph nodes are the nodes of the true pelvis, wh    | ich es            | sentially are the  |  |  |  |  |  |
| pelvic nodes below the bifurcation of the common iliac arteries. They include: pelvic |        |  |                   |  |  |  |  |  |  |
|   |        | NOS, hypogastric, obturator, iliac (internal, external, or NOS), | sacral            | (lateral presacral   |  |  |  |  |  |
|   |        | promontory [Gerota's], or NOS). Laterality does not affect the   | N clas            | ssification  |  |  |  |  |  |
| NX  | Regio  | nal lymph nodes were not assessed                                |                   | Regional nodes not sampled   |  |  |  |  |  |
| NO  | No reg | gional lymph node metastasis                                     |                   | No positive regional nodes   |  |  |  |  |  |
| N1  | Metas  | tasis in regional lymph nodes(s)                                 | pN1               |  |  |  |  |  |  |
| М   | DICTA  | NT METACTACIO :  | 600               | 3 (0)  |  |  |  |  |  |
| MX  |        | NT METASTASIS *  | рM                | DISTANT METASTASIS *   |  |  |  |  |  |
| IVIX  | any m  | nt metastasis cannot be assessed (not evaluated by odality)      | pMX               | Distant metastasis cannot be assessed (not   |  |  |  |  |  |
| МО  |        | odanty)<br>stant metastasis                                      |                   | evaluated by any modality)   |  |  |  |  |  |
| M1  |        | it metastasis  |                   | No distant metastasis  |  |  |  |  |  |
| 1411  | 1a     |  | pM1               | The state of the s |  |  |  |  |  |
|   | 1b     | Non-regional lymph node(s)<br>Bone(s)                            |                   | 1a Non-regional lymph node(s)  |  |  |  |  |  |
|   | 1c     | Other site(s) with or without bone disease                       |                   | 1b Bone(s)   |  |  |  |  |  |
|   | 10     |  |                   | 1c Other site(s) with or without bone disease  |  |  |  |  |  |
|   |        | * When more than one site of metastasis is pre                   | esent, 1          | tne most advanced  |  |  |  |  |  |
|   |        | category is used. pM1c is most                                   | advan             | ncea   |  |  |  |  |  |

#### GRADE

Gleason grade is to be assigned by a pathologist Gleason grade = Primary No. + Secondary Pattern No.